Overview

Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

This is a randomized controlled study to assess the effect of atorvastatin and omega 3 combination therapy compared with atorvastatin and ezetimibe combination therapy in Korean T2DM patients with asymptomatic atherosclerosis.

Phase:

Phase 4

Details

Lead Sponsor:

Seoul National University Bundang Hospital

Collaborator:

Korea United Pharm. Inc.

Treatments:

Atorvastatin
Ezetimibe